May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs and healthcare resource utilization (HCRU) among...
Antiplatelet and Anticoagulation Therapies
-
-
May 12, 2017 – A new study found that dementia rates increase with delays in starting anticoagulation treatment for...
-
March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood clots around the valve leaflets (known as subclinical leaflet thrombosis) that...
-
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc. first-in-class Cobra PzF NanoCoated Coronary Stent System.
News | Antiplatelet and Anticoagulation Therapies | May 31, 2017
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare...
Feature | Antiplatelet and Anticoagulation Therapies | May 12, 2017
May 12, 2017 – A new study found that dementia rates increase with delays in starting anticoagulation treatment for...
Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.
Feature | Point of Care Testing | May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on...
Feature | Atrial Fibrillation | March 29, 2017
March 29, 2017 — Uninterrupted treatment with dabigatran (Pradaxa), a non-vitamin K,...
News | Antiplatelet and Anticoagulation Therapies | March 27, 2017
March 27, 2017 — Using genetic...
News | Antiplatelet and Anticoagulation Therapies | March 23, 2017
March 23, 2017 — Bleeding complications did not increase for patients with acute coronary syndrome treated with...
News | Antiplatelet and Anticoagulation Therapies | March 23, 2017
March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low...
A CT study from the RESOLVE Trial showing valve leaflet thrombosis on a TAVR device. The trial examined a range of surgical and transcatheter valves to show thrombosis is found across both types of devices. It also examined if anticoagulation or antiplatelet therapy could reduce thrombosis and allow a greater range of leaflet motion.
Feature | Heart Valve Technology | March 21, 2017
March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood...
News | Antiplatelet and Anticoagulation Therapies | March 14, 2017
March 14, 2017 — More than 80 percent of stroke patients with a history of...
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc. first-in-class Cobra...
News | Antiplatelet and Anticoagulation Therapies | February 09, 2017
February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is...
News | Antiplatelet and Anticoagulation Therapies | January 17, 2017
January 17, 2017 — Warfarin is a commonly prescribed...
News | Antiplatelet and Anticoagulation Therapies | January 11, 2017
January 11, 2017 — For patients with...
The Xprecia Stride Coagulation Analyzer delivers fast, reliable prothrombin time/international normalized ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist. It is the latest INR testing system to enter the market in late 2016. Read the article “Siemens Receives FDA Clearance of Xprecia Stride Coagulation Analyzer.”
Feature | Point of Care Testing | December 30, 2016 | Ravi Chawat
Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology...
